Início › Câncer (todos os tipos) › Michigan › Detroit
Ensaios clínicos de Câncer (todos os tipos) em Detroit, MI
29 estudos para Câncer (todos os tipos) estão buscando participantes em locais em Detroit e arredores (num raio de aproximadamente 30 milhas). Abra um estudo para ver quem pode participar e como contatar a equipe.
Texto oficial do estudo (Inglês)
Recrutando participantes para um estudo? Destaque-o no topo desta página — $99 por 30 dias →
A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With Gastric Cancer
RecrutandoFase 3
- Barbara Ann Karmanos Cancer Center, Detroit
- Henry Ford Cancer Institute-Henry Ford Hospital, Detroit
Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)
RecrutandoFase 3
- Karmanos Cancer Center ( Site 0108), Detroit
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
RecrutandoFase 2
- Henry Ford Health Saint John Hospital, Detroit
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
RecrutandoFase 2/3
- Karmanos Cancer Center Wayne State University, Detroit
Connect for Cancer Prevention Study (Connect)
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
- Henry Ford Health Systems, Detroit
A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
RecrutandoFase 1/2
- GSK Investigational Site, Detroit
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RecrutandoFase 1
- Henry Ford Cancer Institute, Detroit
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
RecrutandoFase 1/2
- Henry Ford Hospital, Detroit
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
RecrutandoEstudo observacional
- Karmanos Cancer Institute, Detroit
Project: Every Child for Younger Patients With Cancer
RecrutandoEstudo observacional
- Children's Hospital of Michigan, Detroit
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
RecrutandoFase 1/2
- Karmanos Cancer Institute, Detroit
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
RecrutandoFase 3
- Henry Ford Health Saint John Hospital, Detroit
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
RecrutandoFase 1/2
- Henry Ford Cancer Institute, Detroit
A Study of ASP1002 in Adults for Treatment of Solid Tumors
RecrutandoFase 1
- Henry Ford Hospital, Detroit
A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid Tumors
RecrutandoFase 1
- Henry Ford Health System, Detroit
Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors
RecrutandoFase 1/2
- Henry Ford Hospital, Detroit
Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplatin (GDP) Salvage Chemotherapy in Relapsed Refractory Large B-cell Lymphoma
RecrutandoFase 2
- Karmanos Cancer Center (Wayne State University), Detroit
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
RecrutandoFase 1/2
- Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion), Detroit
A Study to Evaluate the Safety,Tolerability, Pharmacokinetics and Clinical Activity of Mocertatug Rezetecan for Injection in Participants With Advanced Solid Tumors (BEHOLD-1)
RecrutandoFase 1
- GSK Investigational Site, Detroit
A Study of GSK5764227 in Participants With Advanced Solid Tumors (EMBOLD)
RecrutandoFase 1
- GSK Investigational Site, Detroit
Safety, PK, and Preliminary Efficacy of MBRC-101 in Advanced Refractory Solid Tumors
RecrutandoFase 1/2
- Karmanos Cancer Institute, Detroit
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
RecrutandoFase 1
- Henry Ford Cancer Institute, Detroit
A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
RecrutandoFase 1/2
- Henry Ford Health, Detroit
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
RecrutandoFase 1
- Karmanos Cancer Institute, Detroit
Addressing Social Determinants of Health Among Metro Detroit Cancer Survivors
Recrutando
- Karmanos Cancer Institute, Detroit
A Beta-only IL-2 ImmunoTherapY Study
RecrutandoFase 1/2
- Karmanos Cancer Institute, Detroit
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
RecrutandoFase 1/2
- Henry Ford Cancer Institute, Detroit
A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
RecrutandoFase 1/2
- Barbara Ann Karmanos Cancer Hospital dba Karmanos Cancer Center, Detroit
RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT
RecrutandoEstudo observacional
- Henry Ford Health System, Detroit
Ensaios de Câncer (todos os tipos) em outras cidades
- Houston, TX121 estudos
- New York City, NY109 estudos
- Boston, MA85 estudos
- Los Angeles, CA74 estudos
- Nashville, TN65 estudos
- Philadelphia, PA59 estudos
- Washington, DC58 estudos
- Durham, NC58 estudos
- Chicago, IL51 estudos
- Atlanta, GA49 estudos
- Seattle, WA49 estudos
- Arlington, VA48 estudos
Outros estudos em Detroit
- Câncer de Pulmão de Não Pequenas Células44 estudos
- Câncer de Mama33 estudos
- Câncer Colorretal26 estudos
- Câncer de Ovário26 estudos
- Câncer Metastático24 estudos
- Câncer de Próstata22 estudos
- Câncer Endometrial21 estudos
- Câncer de Pulmão20 estudos
- Mieloma Múltiplo19 estudos
- Câncer de Estômago16 estudos
- Carcinoma de Células Escamosas de Cabeça e Pescoço15 estudos
- Leucemia Mieloide Aguda14 estudos
Fonte: ClinicalTrials.gov, dados obtidos em 6 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.